|
|
News Breaks
|
October 30, 2009
|
| 16:11 EDT |  | CYCC |
| theflyonthewall.com: | Cyclacel Pharmaceuticals receives deficiency notice from Nasdaq | | Cyclacel Pharmaceuticals announced that it received a Nasdaq Staff Deficiency Letter on October 27 indicating that the company fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 5450(a)(1). The letter gives Cyclacel notice that the company's bid price of its common stock has closed under $1.00 for the last 30 business days. The Nasdaq notice has no effect on the listing of the Company's common stock at this time. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the company has an initial period of 180 calendar days, or until April 26, 2010, to regain compliance. The letter states the Nasdaq staff will provide written notification that the company has achieved compliance with Rule 5450(a)(1) if at any time before April 26, 2010, the bid price of the company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days. :theflyonthewall.com |
|
|
News For CYCC From The Last 14 Days Check below for free stories on CYCC the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 8, 2012
|
| 07:42 EDT |  | CYCC |
| theflyonthewall.com: | Cyclacel Pharmaceuticals management to meet with Lazard Capital | | Meeting to be held in Boston on February 10 hosted by Lazard Capital. :theflyonthewall.com |
|
|
|
|
|
